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Triglyceride levels and their role in ischemic 
stroke are the topic of intense research 
(Leonards et al., 2010). Large-scale epide-
miological studies with more than 10,000 
participants each were able to detect an 
association between triglycerides and 
stroke risk (Bansal et al., 2007; Freiberg 
et al., 2008). Specifically, such studies have 
revealed a relationship between non-fasting 
triglyceride levels and ischemic stroke risk. 
However, the results of studies in smaller 
cohorts remain inconclusive (Leonards 
et al., 2010). Are large studies necessary to 
detect an effect of non-fasting triglycerides 
because triglycerides exhibit a relatively 
weak influence on stroke risk or are there 
other factors involved?
Even in a primary care cohort of 6,621 
unselected patients, taken from the pro-
spective cohort DETECT study (diabetes 
cardiovascular risk-evaluation: targets and 
essential data for commitment of treat-
ment), we struggled to replicate findings 
from the larger studies (Bansal et al., 2007; 
Freiberg et al., 2008). Details of the DETECT 
study design can be found elsewhere (Pieper 
et al., 2005; Wittchen et al., 2005; Schneider 
et al., 2008). Briefly, however, triglyceride 
levels were measured in venous blood sam-
ples taken at time of patient enrolment 
using a Roche Modular automatic analyzer 
(Roche Diagnostics Scandinavian, Bromma, 
Sweden). Fasting was defined as having 
eaten no earlier than 8 h prior to phlebot-
omy. The endpoint chosen for this analysis 
was incident ischemic stroke as reported by 
physicians and/or patients occurring in the 
4–5 years follow-up period.
Consistent with Freiberg et al. (2008), 
triglyceride levels were stratified into 
quintiles (<89, 89–176, 177–265, 266–353, 
and ≥354 mg/dL). Hazard ratios (HRs) 
were then calculated by Cox propor-
tional hazard model for individual strata 
of triglycerides and verified by Schoenfeld 
residuals. Additionally, HRs were calcu-
lated for dimensional triglyceride levels 
(increase of 1 SD) and scaled to an increase 
of 89 mg/dL for interpretation to follow 
(Freiberg et al., 2008). Also for reasons of 
comparison, age, total cholesterol, alco-
hol consumption, smoking, hypertension, 
atrial fibrillation, lipid lowering therapy, 
diabetes, BMI, and HDL were included 
in triglyceride analyses (Freiberg et al., 
2008). Because of the low incidence base 
rate of 97 strokes (23 in women), we 
applied a forward stepping algorithm to 
minimize covariates and avoided over-
adjustment (Triglyceride Cononary 
Disease Consortium and Emerging Risk 
Factors Collaboration, 2010) using a mini-
mum triglyceride HR change of 5% as an 
inclusion criterion of a covariate into the 
model. All statistical analyses were con-
ducted with the software package STATA 
10.2 (Stata Corp.).
We found in the unadjusted model and 
models adjusted for age only, a significant 
association of fasting triglyceride levels with 
ischemic stroke in women (HR 1.2, 95% CI 
1.2–1.4, p < 0.01) but not in men (HR 1.0, 
95% CI 0.8–1.1, p > 0.5). This finding con-
curred with two long term cohort studies 
from Japan (Iso et al., 2007) and Norway 
(Njolstad et al., 1996) suggesting a possible 
gender difference in triglycerides’ predictive 
role for stroke. No significant association 
between fasting or non-fasting triglycerides 
and stroke was found however after multi-
ple adjustments (Table 1).
Our study may have been underpow-
ered and the low number of events was a 
major limitation. A post hoc power analy-
sis revealed a 13.1% chance of incorrectly 
rejecting the null hypothesis at a 95% 
confidence interval. Based on these find-
ings, one may conclude that if any the 
 relationship between triglycerides and 
stroke is relatively weak and possibly lim-
ited to females.
Overall, however, the association of fast-
ing and non-fasting triglyceride levels with 
stroke remains inconclusive. Despite sev-
eral proposed mechanisms describing how 
triglycerides might possibly increase the risk 
of stroke (Papagianni et al., 2004; Karepov 
et al., 2008), the observed associations 
between triglycerides and vascular events 
do not provide much support of a causal 
relationship (Third Report of the National 
Cholesterol Education, 2002). On the other 
hand, a generalized lack of standardization 
could explain the discrepancies between 
our results and other studies. Neither time 
points of blood draws after the last meal nor 
the content of that meal have been standard-
ized in most of the studies discussed here. 
We therefore advocate a more standardized 
approach to future research in an effort to 
garner meaningful outcomes without need-
ing to include tens of thousands of partici-
pants. A prospective study (Ebinger et al., 
2010), using a novel oral triglyceride toler-
ance test (blood draws after a 10 h fast and 
3 h after intake of 250 mL of 32% fat cream) 
to test this theory and thereby circumvent 
the possible problems associated with a lack 
of standardization is currently under way.
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Table 1 | Increase of the hazard with every increase of dimensional triglyceride levels by 89 mg/dL and 1 SD in both fasting and non-fasting men 
and women.
Gender Analyses Increase of triglyceride level Increase of triglyceride level by 1 SD 
  by 89 mg/dL
  HR 95% CI p-Value HR 95% CI p-Value
Fasting women Adjustment 1† 1.2 1.1–1.4 0.001 1.3 1.1–1.6 0.001
 Adjustment 2‡ 1.2 1.1–1.4 0.002 1.3 1.1–1.6 0.002
 Adjustment 3¶ 1.1 1.0–1.3 0.162 1.2 0.9–1.5 0.162
Fasting men Adjustment 1† 1.0 0.8–1.1 0.574 0.9 0.7–1.2 0.574
 Adjustment 2‡ 1.0 0.9–1.2 0.869 1.0 0.8–1.2 0.869
 Adjustment 3¶ 1.0 0.8–1.2 0.722 0.9 0.7–1.3 0.722
Non-fasting women Adjustment 1† 1.0 0.7–1.2 0.779 0.9 0.6–1.4 0.779
 Adjustment 2‡ 0.9 0.6–1.2 0.403 0.8 0.5–1.4 0.403
 Adjustment 3¶ 0.7 0.5–1.1 0.137 0.6 0.3–1.2 0.137
Non-fasting men Adjustment 1† 0.9 0.7–1.1 0.269 0.8 0.6–1.2 0.269
 Adjustment 2‡ 0.9 0.7–1.2 0.625 0.9 0.6–1.3 0.625
 Adjustment 3¶ 0.8 0.5–1.2 0.307 0.7 0.3–1.4 0.307
CI, confidence interval; HR, hazard ratio estimated by Cox proportional hazard model.
†Crude, ‡age, ¶fasting women: age, cholesterol, lipid lowering therapy, HDL; fasting men: age, cholesterol, HDL,diabetes; non-fasting women: age, cholesterol, HDL, 
diabetes, BMI; non-fasting men: age, cholesterol, lipid lowering therapy, diabetes, hypertension, BMI.
Bold print indicates that the p-value for the corresponding HR is <0.05.
